Comparing Effect and Change Processes in Cognitive Behavioral Therapy and Emotion-Focused Therapy for Depression

March 5, 2024 updated by: Institutt for Psykologisk Radgivning

Randomized Controlled Study Comparing the Therapeutic Effect and Change Processes in Cognitive Behavioral Therapy and Emotion-Focused Therapy for Depression

Depression is a common mental illness which is costly for both society and for those affected. There is a need for effective treatments of depression and there is a need to make sure that the treatments that are given are based on scientific findings. In this study the investigators want to examine and compare two common treatment models for depression - Cognitive Behavioral Therapy and Emotion-Focused Therapy. The investigators want to investigate what characterizes these treatments when they are successful, and seek to better understand what it is like for patients to receive these treatments. Also, the investigators will investigate the experience of patients who abruptly discontinue treatment. To investigate these questions, self-report measures, interviews and analysis of session recordings will be used.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Depression is a widespread mental disorder which can result in severe impairment and reduced quality of life for those affected. Cognitive behavioral therapy (CBT) is the approach with strongest empirical support, and is often recommended as treatment for depression, as in the NICE Guidelines for Depression from 2009. However, research indicates that not all patients respond to CBT, indicating a need to expand the range of available evidence-based psychotherapies, and mapping the mechanisms of change in existing treatments.

Emotion focused therapy (EFT) is one promising treatment for depression with empirical support for its efficacy. A previous study found equal outcome in CBT and Process-Experiential treatment/EFT for depression, but more studies are needed to replicate these findings across cultural contexts. The main aim of this study is to investigate whether there are significant differences in the therapeutic effect of EFT compared to that of CBT for patients with moderate and major depressive disorder in a Norwegian outpatient setting.

Although several psychotherapeutic approaches have shown efficacy in the treatment of depression, no psychotherapeutic interventions is beneficial for all patients. There is a need for research that investigates what treatments works for whom, based on patient characteristics and preferences. The present study will investigate whether patient characteristics moderate treatment outcome, both within and between treatment conditions. In addition, qualitative interviews will be conducted to get a deeper understanding of what clients find helpful and challenging within the CBT and EFT condition, and to explore the experience of patients who drop-out of the treatment process.

In order to further develop psychotherapeutic treatments and increase their effectiveness, there is a need to identify processes that are related to good and poor outcome. Process-outcome studies are commonly used for this purpose. The present study will investigate and compare characteristics of psychotherapy processes in both the CBT and EFT conditions and how these are related to outcome.

Study design and Method

The study will be conducted as a randomized controlled trial (RCT) in order to compare the efficacy of EFT to CBT. RCT's are considered the gold standard for efficacy studies. Participants will be recruited from the Norwegian mental health program "Return to work", a publicly funded treatment program where patients with common mental health issues receives outpatient psychotherapeutic treatment to reduce and prevent sick leave.

The present study will address the following research hypothesis and questions:

  1. EFT and CBT will not result in significantly different outcome in the treatment of patients with moderate and major depressive disorder.
  2. Patient characteristics (severity of depression, adverse childhood experiences and clients' initial ability to make sense of their experience) will moderate treatment outcome for both conditions.
  3. Will therapeutic processes (therapeutic alliance, therapist empathy, clients' ability to make sense of their experience and emotional processing) mediate treatment outcome equally for both conditions?
  4. What do patients in both conditions describe as helpful and unhelpful aspects of treatment?
  5. How do patients in both conditions describe their own change or lack or change after treatment?
  6. How do patients that choose to drop out of treatment describe the processes leading to that decision?

Study Type

Interventional

Enrollment (Actual)

112

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Jan R Stiegler, PhD
  • Phone Number: +4792211019
  • Email: stiegler@ipr.no

Study Contact Backup

  • Name: Hanna Aardal, Cand Psychol
  • Phone Number: +4795287217
  • Email: aardal@ipr.no

Study Locations

      • Bergen, Norway, 5012
        • Institutt for Psykologisk rådgivning

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- Moderate or major depressive episode as primary diagnosis

Exclusion Criteria:

  • Serious mental illness (schizophrenia, severe bipolar disorder, recent or current psychotic episode) or intellectual disability.
  • Severe alcohol or drug abuse, last 12 months.
  • Suicidality last 6 months
  • Severe medical issues
  • If the participant is on antidepressive medication, the dosage must have been stable for more than 4 weeks, and the participant must consent to staying on the same dosage for the duration of the treatment.
  • The participant is currently in another treatment for depression

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Cognitive Behavioral Therapy
14-18 sessions of psychotherapy according to principles of Cognitive Behavioral Therapy
14-18 sessions of CBT
Other Names:
  • CBT
Active Comparator: Emotion-Focused Therapy
14-18 sessions of psychotherapy according to principles of Emotion Focused Therapy
14-18 sessions of EFT
Other Names:
  • EFT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Beck Depression Inventory from session to session
Time Frame: 1 week before treatment startup, 1 day after each therapy session, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of depressive symptoms, ranging from minimum 0 and maximum 63. Higher scores suggests worse outcome.
1 week before treatment startup, 1 day after each therapy session, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Beck Anxiety Inventory
Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of anxiety symptoms, ranging from minimum 0 and maximum 63. Higher scores suggests worse outcome.
1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Change in Repetitive Eating Questionnaire
Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of symptoms related to eating disorders, average scores, minimum 0, maximum 6, higher score indicates worse outcome.
1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Change in Inventory of Interpersonal problems
Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of interpersonal difficulties, average scores minimum 0, maximum 4. Higher score suggests worse outcome.
1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Change in The Acceptance and Action Questionnaire from session to session
Time Frame: 1 week before treatment startup, 1 day after each therapy session, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of psychological flexibility, average scores minimum 1, maximum 7. Higher score suggests worse outcome.
1 week before treatment startup, 1 day after each therapy session, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Change in Emotion Approach Coping Scale
Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of emotional processing ability, average scores minimum 1, maximum 4. Higher score suggests better outcome.
1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Change in Penn State Worry Questionaire
Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of rumination and cognitive processing, total scores minimum 16, maximum 80. Higher score suggests worse outcome.
1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Change in Self-Compassion Scale
Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of self-relating, average scores, minimum 1, maximum 5, higher scores suggests better outcome.
1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Change in Quality of life questionnaire
Time Frame: 1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Self-report measure of quality of life, average scores, minimum 1, maximum 5, higher scores indicate better outcome.
1 week before treatment startup, within 1 week after treatment, 3 month follow up, 6 month follow up, 12 months follow up
Change in Working Alliance Inventory - short version
Time Frame: 1 day after 1st through 14th therapy session.
Self report measure on experience of therapeutic alliance, average scores, minimum 1, maximum 7, higher scores suggests better outcome.
1 day after 1st through 14th therapy session.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Jan Reidar Stiegler, PhD, Institute for Psychological Counselling

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 20, 2021

Primary Completion (Estimated)

July 30, 2024

Study Completion (Estimated)

July 30, 2024

Study Registration Dates

First Submitted

December 16, 2020

First Submitted That Met QC Criteria

December 27, 2020

First Posted (Actual)

December 31, 2020

Study Record Updates

Last Update Posted (Estimated)

March 6, 2024

Last Update Submitted That Met QC Criteria

March 5, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • IPR

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Cognitive Behavioral Therapy

3
Subscribe